JINXIN FERT.GRP HD-00001 (3NX) - Net Assets
Based on the latest financial reports, JINXIN FERT.GRP HD-00001 (3NX) has net assets worth €9.25 Billion EUR (≈ $10.82 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€14.01 Billion ≈ $16.38 Billion USD) and total liabilities (€4.76 Billion ≈ $5.56 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of JINXIN FERT.GRP HD-00001 to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €9.25 Billion |
| % of Total Assets | 66.05% |
| Annual Growth Rate | 5.76% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.53 |
JINXIN FERT.GRP HD-00001 - Net Assets Trend (2021–2024)
This chart illustrates how JINXIN FERT.GRP HD-00001's net assets have evolved over time, based on quarterly financial data. Also explore JINXIN FERT.GRP HD-00001 (3NX) total assets for the complete picture of this company's asset base.
Annual Net Assets for JINXIN FERT.GRP HD-00001 (2021–2024)
The table below shows the annual net assets of JINXIN FERT.GRP HD-00001 from 2021 to 2024. For live valuation and market cap data, see market cap of JINXIN FERT.GRP HD-00001.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €10.35 Billion ≈ $12.11 Billion |
+1.64% |
| 2023-12-31 | €10.19 Billion ≈ $11.91 Billion |
+16.62% |
| 2022-12-31 | €8.74 Billion ≈ $10.21 Billion |
-0.20% |
| 2021-12-31 | €8.75 Billion ≈ $10.23 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to JINXIN FERT.GRP HD-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 55.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.71 Billion | 16.65% |
| Other Components | €8.56 Billion | 83.35% |
| Total Equity | €10.27 Billion | 100.00% |
JINXIN FERT.GRP HD-00001 Competitors by Market Cap
The table below lists competitors of JINXIN FERT.GRP HD-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GKHT Medical Technology Co. Ltd. A
SHE:301370
|
$721.00 Million |
|
Nanosonics Ltd
AU:NAN
|
$721.18 Million |
|
Winstek Semiconductor Co Ltd
TWO:3265
|
$721.22 Million |
|
M31 Technology Corp
TWO:6643
|
$721.52 Million |
|
Ray Sigorta AS
IS:RAYSG
|
$720.61 Million |
|
John B Sanfilippo & Son Inc
NASDAQ:JBSS
|
$720.58 Million |
|
Cubic Sensor and Instrument Co Ltd
SHG:688665
|
$720.40 Million |
|
Shenzhen Sunwin Intelligent
SHE:300044
|
$719.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in JINXIN FERT.GRP HD-00001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,091,423,000 to 10,274,419,000, a change of 182,996,000 (1.8%).
- Net income of 283,099,000 contributed positively to equity growth.
- Dividend payments of 150,000,000 reduced retained earnings.
- Share repurchases of 51,313,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €283.10 Million | +2.76% |
| Dividends Paid | €150.00 Million | -1.46% |
| Share Repurchases | €51.31 Million | -0.5% |
| Other Changes | €101.21 Million | +0.99% |
| Total Change | €- | 1.81% |
Book Value vs Market Value Analysis
This analysis compares JINXIN FERT.GRP HD-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.41 | €0.25 | x |
| 2022-12-31 | €3.43 | €0.25 | x |
| 2023-12-31 | €3.71 | €0.25 | x |
| 2024-12-31 | €3.84 | €0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently JINXIN FERT.GRP HD-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.07%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.46x
- Recent ROE (2.76%) is below the historical average (2.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 3.98% | 18.48% | 0.14x | 1.50x | €-514.63 Million |
| 2022 | 1.40% | 5.12% | 0.16x | 1.76x | €-742.85 Million |
| 2023 | 3.42% | 12.36% | 0.19x | 1.48x | €-664.42 Million |
| 2024 | 2.76% | 10.07% | 0.19x | 1.46x | €-744.34 Million |
Industry Comparison
This section compares JINXIN FERT.GRP HD-00001's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $8,223,839,896
- Average return on equity (ROE) among peers: -82.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| JINXIN FERT.GRP HD-00001 (3NX) | €9.25 Billion | 3.98% | 0.51x | $720.78 Million |
| China Resources Medical Holdings Company Limited (1PH) | $7.00 Billion | 1.99% | 0.59x | $428.88 Million |
| AEST.MED.INT.HLD.SP.ADR/3 (3FMA) | $-186.42 Million | 0.00% | 0.00x | $3.30 Million |
| REVITALIST L.A.W. LTD (4DO) | $1.87 Million | -771.24% | 4.54x | $744.60K |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.34 Billion | 4.88% | 1.24x | $19.18 Million |
| Bumrungrad Hospital Public Company Limited (BZ7A) | $31.17 Billion | 24.10% | 0.17x | $50.87K |
| Eifelhöhen-Klinik AG (EIF) | $9.88 Million | -19.11% | 6.64x | $8.99 Million |
| Fresenius Medical Care AG & Co. KGaA (FME) | $2.69 Billion | 11.01% | 1.18x | $12.02 Billion |
| Fresenius Medical Care AG & Co. KGaA (FMEA) | $12.33 Billion | 9.44% | 1.57x | $11.58 Billion |
| Fresenius SE & Co. KGaA (FRE) | $19.65 Billion | -3.02% | 1.30x | $27.16 Billion |
About JINXIN FERT.GRP HD-00001
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. It offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF … Read more